BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegenera
Family of NLRP3 inhibitors is differentiated by novel structure, central nervous system penetration, and potential for improved safety and efficacyRICHMOND, Calif.--(BUSINESS WIRE)--#aging--BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the mol...
Source: pharmiweb.com